MedPath

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Phase 2
Recruiting
Conditions
Ulcerative Colitis
Interventions
Registration Number
NCT05287126
Lead Sponsor
Pfizer
Brief Summary

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
EtrasimodEtrasimod-
Primary Outcome Measures
NameTimeMethod
Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52Week 52
Secondary Outcome Measures
NameTimeMethod
Proportion of Participants Achieving Clinical Response at Week 12Week 12
Proportion of Participants Achieving a Clinical Response as Assessed by PUCAI at Week 12Week 12
Plasma Concentration of Etrasimod at 4 Hours Post-dose (C4h)4 hours (± 15 minutes) post-dose
Proportion of Participants Achieving Clinical Remission by Pediatric Ulcerative Colitis Activity Index (PUCAI) at Week 12Week 12
Proportion of Participants Achieving a Clinical Response as Assessed by PUCAI at Week 52Week 52
Proportion of Participants Achieving Endoscopic Improvement at Week 12Week 12
Proportion of Participants Achieving Symptomatic Remission at Week 52Week 52
Proportion of Participants with Clinical Remission at Week 12 Who Had Not been Receiving Corticosteroids for ≥ 2 weeks Prior to Week 12Week 12
Plasma Steady State Trough Concentration (Ctrough,ss) of Etrasimodpre-dose and 4 hours (±15 minutes) post-dose at Day 1; at trough concentrations (approximately 24 hours after the dose taken the day before the study visit) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
Proportion of Participants with Clinical Remission at Week 52 Who Had Not been Receiving Corticosteroids for ≥ 12 weeks Prior to Week 52Week 52
Proportion of Participants Achieving Clinical Response at Week 52Week 52
Number and Severity of Adverse EventsUp to Week 52

Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.

Proportion of Participants Achieving Clinical Remission as Assessed by PUCAI at Week 52Week 52
Proportion of Participants Achieving Endoscopic Improvement at Week 52Week 52
Proportion of Participants Achieving Symptomatic Remission at Week 12Week 12
Proportion of Participants Achieving Clinical Remission as Assessed by MMS at Week 12Week 12

Trial Locations

Locations (47)

Centrum Zdrowia MDM

🇵🇱

Warszawa, Poland

Narodny ustav detskych chorob

🇸🇰

Bratislava, Bratislavský KRAJ, Slovakia

Arkansas Children's (IP Address)

🇺🇸

Little Rock, Arkansas, United States

Arkansas Children's

🇺🇸

Little Rock, Arkansas, United States

Valley View Wellness Medical Center

🇺🇸

Garden Grove, California, United States

Loma Linda Children's Hospital

🇺🇸

Loma Linda, California, United States

Loma Linda University Clinical Trial Center

🇺🇸

Loma Linda, California, United States

Loma Linda University Eye Institute

🇺🇸

Loma Linda, California, United States

Loma Linda University Medical Center

🇺🇸

Loma Linda, California, United States

Loma Linda University Pediatric Clinics

🇺🇸

Loma Linda, California, United States

Loma Linda University Children's Hospital Pediatric Specialty Clinics

🇺🇸

San Bernardino, California, United States

University of California San Francisco,

🇺🇸

San Francisco, California, United States

University of California San Francisco

🇺🇸

San Francisco, California, United States

University of California,San Francisco Pediatric ClinicalResearch Center (PCRC)

🇺🇸

San Francisco, California, United States

Arnold Palmer Hospital - Center for Digestive Health and Nutrition

🇺🇸

Orlando, Florida, United States

University of Chicago Medical Center

🇺🇸

Chicago, Illinois, United States

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

William Beaumont Hospital

🇺🇸

Royal Oak, Michigan, United States

Dartmouth Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

University of Rochester Medical Center

🇺🇸

Rochester, New York, United States

University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital

🇺🇸

Cleveland, Ohio, United States

University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

Advance Clinical Trial PLLC

🇺🇸

Abilene, Texas, United States

Landeskrankenhaus Salzburg

🇦🇹

Salzburg, Austria

University Hospitals Leuven

🇧🇪

Leuven, Belgium

Tsujinaka Hospital - Kashiwanoha

🇯🇵

Kashiwa, Chiba, Japan

Ishii Eye Clinic

🇯🇵

Nagareyama-shi, Chiba, Japan

Gunma University Hospital

🇯🇵

Maebashi, Gunma, Japan

Hyogo Medical University Hospital

🇯🇵

Nishinomiya, Hyogo, Japan

Kinki University - Nara Hospital

🇯🇵

Ikoma City, Nara, Japan

Saitama Prefectural Children's Medical Center

🇯🇵

Saitama-shi, Saitama, Japan

Jichi Medical University Hospital

🇯🇵

Shimotsuke, Tochigi, Japan

Juntendo University Hospital

🇯🇵

Bunkyo-ku, Tokyo, Japan

Japanese Red Cross Kyoto Daini Hospital

🇯🇵

Kyoto, Japan

Saga University Hospital

🇯🇵

Saga, Japan

Toyama Prefectural Central Hospital

🇯🇵

Toyama, Japan

Instytut "Pomnik - Centrum Zdrowia Dziecka" (IPCZD) (The Children's Memorial Health Institute)

🇵🇱

Warsaw, Mazowieckie, Poland

Uniwersytecki Szpital Dziecięcy w Krakowie

🇵🇱

Krakow, Poland

Twoja Przychodnia - Szczecińskie Centrum Medyczne

🇵🇱

Szczecin, Poland

WIP Warsaw IBD Point Profesor Kierkus

🇵🇱

Warsaw, Poland

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

🇵🇱

Wroclaw, Poland

Instytut Centrum Zdrowia Matki Polki

🇵🇱

Lodz, Łódzkie, Poland

Cliniq s.r.o.

🇸🇰

Bratislava, Slovakia

Hospital Clinico Universitario de Santiago de Compostela

🇪🇸

Santiago de Compostela, A Coruna, Spain

Consorci Corporacio Sanitaria Parc Tauli

🇪🇸

Sabadell, Barcelona, Spain

Hospital Universitari Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital Reina Sofia

🇪🇸

Cordoba, Spain

© Copyright 2025. All Rights Reserved by MedPath